The Exchange has sought clarification from Cipla Limited with respect to recent news item captioned Cipla shares fall 4% as partner gets US FDA observations. The response from the Company is attached.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty 100 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cipla has clarified that its supply partner Pharmathen International S.A. received 9 USFDA inspectional observations (Form 483) following an inspection at its Rodopi, Greece manufacturing facility from 10th November to 21st November 2025. Pharmathen manufactures Lanreotide Injection for Cipla USA Inc., Cipla's wholly-owned subsidiary. The clarification was issued after the stock exchanges sought a response following media reports that dragged Cipla's share price down by around 4%. The company has stated it is currently evaluating the impact of this event and will update the exchanges if any material impact is identified.
This is a supply-chain compliance risk. While Form 483 observations are not a ban or import alert by themselves, any escalation (like a Warning Letter or import alert) could disrupt supply of Lanreotide to the US market and affect Cipla USA's revenue. Investors should watch for further updates on the severity classification of the observations and any remediation timeline from Pharmathen.